After Thirty Years, We Still Cannot Understand Why Methylene Blue is not a Reference to Treat Vasoplegic Syndrome in Cardiac Surgery
AUTOR(ES)
Evora, Paulo Roberto B.; Soares, Ricardo O. S.; Bassetto, Solange; Martins, Maria Auxiliadora; Silva, Fábio Luis da Silva; Basile Filho, Anibal
FONTE
Braz. J. Cardiovasc. Surg.
DATA DE PUBLICAÇÃO
2021-06
RESUMO
Abstract Vasoplegic syndrome (VS) comprises a constellation of concurrent signs and symptoms: hypotension, high cardiac index, low systemic vascular resistance, low filling pressures, the tendency to occur diffuse bleeding, and sustained hypotension. All of these parameters may persist even despite the use of high doses of vasoconstrictor amines. VS arises from vasoplegic endothelial dysfunction with excessive release of nitric oxide by polymorphonuclear leukocytes mediated by the nitric oxide synthase’s inducible form and is associated with systemic inflammatory reaction and high morbimortality. The achievements regarding the treatment of VS with methylene blue (MB) are a valuable Brazilian contribution to cardiac surgery. The present text review was designed to deliver the accumulated knowledge in the past ten years of employing MB to treat VS after cardiac surgery. Considering that we have already published two papers describing acquired experiences and concepts after 15 and 20 years, now, as we achieve the 30-year mark, we compose a trilogy.
Documentos Relacionados
- Clostridium difficile Testing: after 20 Years, Still Challenging
- Why Methylene Blue Is the Only Option for Blocking the cGMP/NO Pathway in The Treatment of Vasoplegic Shock? “Reasons That Reason Itself Does Not Know…”
- Vasoplegic Syndrome after Off-Pump Coronary Artery Bypass Surgery: An Unusual Complication
- Methylene Blue to Treat Protamine-induced Anaphylaxis Reactions. An Experimental Study in Pigs
- AIDS: After 20 years, complacency